8a-Phenyldecahydroquinoline (8A-PDHQ) is a high affinity NMDA antagonist developed by a team at Parke Davis in the 1950s. It is a structural analog of Phencyclidine with slightly lower binding affinity than the parent compound. (-)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-MK-801.
^Chen C; Kozikowski AP; Wood PL; Reynolds IJ; Ball RG; Pang YP (1992). "Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency". Journal of Medicinal Chemistry. 35 (9): 1634–8. doi:10.1021/jm00087a020. PMID1315871.
^Elhallaoui M; Laguerre M; Carpy A; Ouazzani FC (2002). "Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode". J Mol Model. 8 (2): 65–72. doi:10.1007/s00894-001-0067-4. PMID12032600.